Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Receivables (2019 - 2025)

Historic Receivables for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $1.2 million.

  • Legend Biotech's Receivables rose 7531.91% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year increase of 7531.91%. This contributed to the annual value of $7.1 million for FY2024, which is 9299.12% down from last year.
  • Legend Biotech's Receivables amounted to $1.2 million in Q3 2025, which was up 7531.91% from $27.6 million recorded in Q2 2025.
  • Legend Biotech's 5-year Receivables high stood at $100.8 million for Q4 2023, and its period low was $15000.0 during Q2 2021.
  • For the 5-year period, Legend Biotech's Receivables averaged around $20.2 million, with its median value being $2.4 million (2021).
  • Examining YoY changes over the last 5 years, Legend Biotech's Receivables showed a top increase of 961396.92% in 2023 and a maximum decrease of 9989.05% in 2023.
  • Over the past 5 years, Legend Biotech's Receivables (Quarter) stood at $100.4 million in 2021, then tumbled by 98.97% to $1.0 million in 2022, then skyrocketed by 9613.97% to $100.8 million in 2023, then tumbled by 92.99% to $7.1 million in 2024, then tumbled by 82.51% to $1.2 million in 2025.
  • Its Receivables stands at $1.2 million for Q3 2025, versus $27.6 million for Q2 2025 and $369000.0 for Q1 2025.